Tags

Type your tag names separated by a space and hit enter

Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
Headache. 2008 Feb; 48(2):210-20.H

Abstract

OBJECTIVE

To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc.) and divalproex sodium (DVPX; DEPAKOTE: Abbott Laboratories) as prophylaxis in reducing disability and impact associated with migraine.

BACKGROUND

There is a need for effective, well-tolerated prophylactic treatment of migraine.

DESIGN/METHODS

This was a randomized, double-blind, single-center prospective study. Fifty-nine patients received either BoNTA 100 U/placebo-DVPX bid or placebo-BoNTA/DVPX 250 mg bid. BoNTA/placebo injections were given at Day 0 and at Month 3. Patients were evaluated at Months 1, 3, 6, and 9.

RESULTS

Both treatments showed significant improvements in migraine disability scores and reductions in headache days and headache index. A trend to decreased headache severity was observed with BoNTA. A greater percentage of DVPX patients reported adverse events possibly related to treatment (DVPX 75.8% vs BoNTA 50%, P = .04) and discontinued because of adverse events (DVPX 27.6% vs BoNTA 3.3%, P = .012).

CONCLUSIONS

Both BoNTA and DVPX significantly reduced disability associated with migraine; BoNTA had a favorable tolerability profile compared with DVPX.

Authors+Show Affiliations

The Neurology Center, Encinitas, CA 92024, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18047502

Citation

Blumenfeld, Andrew M., et al. "Botulinum Toxin Type a and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine." Headache, vol. 48, no. 2, 2008, pp. 210-20.
Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;48(2):210-20.
Blumenfeld, A. M., Schim, J. D., & Chippendale, T. J. (2008). Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache, 48(2), 210-20.
Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum Toxin Type a and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. Headache. 2008;48(2):210-20. PubMed PMID: 18047502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. AU - Blumenfeld,Andrew M, AU - Schim,Jack D, AU - Chippendale,Thomas J, Y1 - 2007/11/28/ PY - 2007/12/1/pubmed PY - 2008/6/14/medline PY - 2007/12/1/entrez SP - 210 EP - 20 JF - Headache JO - Headache VL - 48 IS - 2 N2 - OBJECTIVE: To compare the efficacy and safety of botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc.) and divalproex sodium (DVPX; DEPAKOTE: Abbott Laboratories) as prophylaxis in reducing disability and impact associated with migraine. BACKGROUND: There is a need for effective, well-tolerated prophylactic treatment of migraine. DESIGN/METHODS: This was a randomized, double-blind, single-center prospective study. Fifty-nine patients received either BoNTA 100 U/placebo-DVPX bid or placebo-BoNTA/DVPX 250 mg bid. BoNTA/placebo injections were given at Day 0 and at Month 3. Patients were evaluated at Months 1, 3, 6, and 9. RESULTS: Both treatments showed significant improvements in migraine disability scores and reductions in headache days and headache index. A trend to decreased headache severity was observed with BoNTA. A greater percentage of DVPX patients reported adverse events possibly related to treatment (DVPX 75.8% vs BoNTA 50%, P = .04) and discontinued because of adverse events (DVPX 27.6% vs BoNTA 3.3%, P = .012). CONCLUSIONS: Both BoNTA and DVPX significantly reduced disability associated with migraine; BoNTA had a favorable tolerability profile compared with DVPX. SN - 0017-8748 UR - https://www.unboundmedicine.com/medline/citation/18047502/Botulinum_toxin_type_A_and_divalproex_sodium_for_prophylactic_treatment_of_episodic_or_chronic_migraine_ L2 - https://doi.org/10.1111/j.1526-4610.2007.00949.x DB - PRIME DP - Unbound Medicine ER -